Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: A comprehensive review

Journal of Immunotoxicology

Volumn 13, Issue 3, 2016, Pages 286-300

  Abdollahi, Elham ^a,b   Tavasolian, Fataneh ^c   Momtazi Borojeni, Amir Abbas ^a   Samadi, Morteza ^b   Rafatpanah, Houshang ^a,d  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TARBIAT MODARES UNIVERSITY   (Iran)

^d AVICENNA RESEARCH INSTITUTE   (Iran)

Author keywords

IL 23R gene; immune mediated diseases; R381Q (rs11209026) polymorphism

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23 RECEPTOR; IL23R PROTEIN, HUMAN; INTERLEUKIN 23; INTERLEUKIN RECEPTOR;

ANKYLOSING SPONDYLITIS; ASTHMA; AUTOIMMUNE DISEASE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR IMMUNITY; CROHN DISEASE; DNA POLYMORPHISM; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC VARIATION; INFLAMMATORY BOWEL DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS ABORTION; TH17 CELL; THYROIDITIS; ULCERATIVE COLITIS; ANIMAL; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANIMALS; ASTHMA; AUTOIMMUNE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-23; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, INTERLEUKIN; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 84962476854     PISSN: 1547691X     EISSN: 15476901     Source Type: Journal    
DOI: 10.3109/1547691X.2015.1115448     Document Type: Review

References (91)

1. E.Abdollahi, F.Tavasolian, N.Ghasemi, S.A.Mirghanizadeh, M.Azizi, M.Ghoryani, M.Samadi. 2015. Association between lower frequency of R381Q variant (rs11209026) in IL-23 receptor gene and increased risk of recurrent spontaneous abortion (RSA). J Immunotoxicol. 12:317–321
2. H17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 15:1090–1100.
3. E.V.Acosta-Rodriguez, G.Napolitani, A.Lanzavecchia, F.Sallusto. 2007. IL-1β and -6, but not TGFβ are essential for the differentiation of IL-17-producing human T-helper cells. Nat Immunol. 8:942–949.
4. P.P.Ahern, C.Schiering, S.Buonocore, M.J.McGeachy, D.J.Cua, K.J.Maloy, F.Powrie. 2010. IL-23 drives intestinal inflammation through direct activity on T-cells. Immunity. 33:279–288.
5. D.Altshuler, M.J.Daly, E.S.Lander. 2008. Genetic mapping in human disease. Science. 322:881–888.
6. H17 cells. J Exp Med. 204:1849–1861.
7. F.Arjmand, M.Samadi. 2016. Association of 14-bp insertion/deletion polymorphism of HLA-G gene with idiopathic recurrent miscarriages in infertility center patients in Yazd, Iran. J Immunotoxicol. 13:249–254.
8. R.N.Baldassano, J.P.Bradfield, D.S.Monos, C.E.Kim, J.T.Glessner, T.Casalunovo, E.C.Frackelton, F.G.Otieno, S.Kanterakis, J.L.Shaner. 2007. Association of variants of the IL–23 receptor gene with susceptibility to pediatric Crohn’s disease. Clin Gastroenterol Hepatol. 5:972–976.
9. M.L.Baptista, H.Amarante, G.Picheth, V.L.Sdepanian, N.Peterson, U.Babasukumar, H.C.Lima, S.Kugathasan. 2008. CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population. Inflamm Bowel Dis. 14:674–679.
10. J.C.Barrett, S.Hansoul, D.L.Nicolae, J.H.Cho, R.H.Duerr, J.D.Rioux, S.R.Brant, M.S.Silverberg, K.D.Taylor, M.M.Barmada. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 40:955–962.
11. C.Becker, H.Dornhoff, C.Neufert, M.Fantini, S.Wirtz, S.Huebner, A.Nikolaev, H.Lehr, A.Murphy, D.Valenzuela. 2006. IL-23 cross-regulates IL-12 production in T-cell-dependent experimental colitis. J Immunol. 177:2760–2764.
12. H17 cells. Nature. 453:1051–1057.
13. H17 cells in the circle of immunity and autoimmunity. Nat Immunol. 8:345–350.
14. H1 lineage. J Immunol. 185:679–687.
15. P.Borgiani, C.Perricone, C.Ciccacci, S.Romano, G.Novelli, L.Biancone, C.Petruzziello, F.Pallone. 2007. IL-23R Arg381Gln is associated with suscepti–bility to Crohn’s disease but not with phenotype in an Italian population. Gastroenterology. 133:1049–1051.
16. S.Brand, F.Beigel, T.Olszak, K.Zitzmann, S.T.Eichhorst, J.-M.Otte, H.Diepolder, A.Marquardt, W.Jagla, A.Popp. 2006. IL-22 is increased in active Crohn’s disease and promotes pro-inflammatory gene expression and intestinal epithelial cell migration. Am J Physiol. 290:G827–G838.
17. C.Büning, J.Genschel, R.Weltrich, H.Lochs, H.Schmidt. 2003. The IL‐25 gene located in the inflammatory bowel disease (IBD) 4 region: No association with inflammatory bowel disease. Eur J Immunogen. 30:329–333.
18. P.R.Burton, D.G.Clayton, L.R.Cardon, N.Craddock, P.Deloukas, A.Duncanson, D.P.Kwiatkowski, M.I.McCarthy, W.H.Ouwehand, N.J.Samani. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 447:661–678.
19. F.Capon, P.di Meglio, J.Szaub, N.J.Prescott, C.Dunster, L.Baumber, K.Timms, A.Gutin, V.Abkevic, A.D.Burden. 2007. Sequence variants in the genes for IL-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Human Genet. 122:201–206.
20. M.Cargill, S.J.Schrodi, M.Chang, V.E.Garcia, R.Brandon, K.P.Callis, N.Matsunami, K.G.Ardlie, D.Civello, J.J.Catanese. 2007. A large-scale genetic association study confirms IL-12B and leads to identification of IL23R as psoriasis-risk genes. Am J Human Genet. 80:273–290.
21. 1/S-phase transition. Leukemia. 22:1557–1566.
22. Y.Chen, C.L.Langrish, B.McKenzie, B.Joyce-Shaikh, J.S.Stumhofer, T.McClanahan, W.Blumenschein, T.Churakovsa, J.Low, L.Presta. 2006. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest. 116:1317–1326.
23. + T-cell precursor. J Exp Med. 205:1903–1916.
24. L.Cotterill, D.Payne, S.Levison, J.McLaughlin, E.Wesley, M.Feeney, H.Durbin, S.Lal, A.Makin, S.Campbell. 2010. Replication and meta-analysis of 13,000 cases defines the risk for IL-23 receptor and autophagy-related 16-like 1 variants in Crohn’s disease. Canad J Gastroenterol. 24:297–305.
25. D.J.Cua, J.Sherlock, Y.Chen, C.A.Murphy, B.Joyce, B.Seymour, L.Lucian, W.To, S.Kwan, T.Churakova. 2003. IL-23 rather than IL-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 421:744–748.
26. P.Di Meglio, A.Di Cesare, U.Laggner, C.-C.Chu, L.Napolitano, F.Villanova, I.Tosi, F.Capon, R.C.Trembath, K.Peris. 2011. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PloS one. 6:e17160.
27. Z.Duan, F.Pan, Z.Zeng, T.Zhang, S.Wang, G.Li, S.Xu, J.Xu, L.Zhang. 2012. IL-23 receptor genetic polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Rheumatol Intl. 32:1209–1214.
28. M.C.Dubinsky, D.Wang, Y.Picornell, I.Wrobel, L.Katzir, A.Quiros, D.Dutridge, G.Wahbeh, G.Silber, R.Bahar. 2007. IL‐23 receptor (IL‐23R) gene protects against pediatric Crohn's disease. Inflamm Bowel Dis. 13:511–515.
29. R.H.Duerr, K.D.Taylor, S.R.Brant, J.D.Rioux, M.S.Silverberg, M.J.Daly, A.H.Steinhart, C.Abraham, M.Regueiro, A.Griffiths. 2006. A genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science. 314:1461–1463.
30. A.Elmaagacli, M.Koldehoff, O.Landt, D.Beelen. 2008. Relation of an IL-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation. Bone Marrow Transplant. 41:821–826.
31. L.R.Ferguson, D.Y.Han, A.G.Fraser, C.Huebner, W.J.Lam, A.R.Morgan. 2010. IL23R and IL12B SNPs and haplotypes strongly associate with Crohn's disease risk in a New Zealand population. Gastroenterol Res Practice. 2010:1–12.
32. J.Fraser Cummings, T.Ahmad, A.Geremia, J.Beckly, R.Cooney, L.Hancock, S.Pathan, C.Guo, L.R.Cardon, D.P.Jewell. 2007. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm Bowel Dis. 13:1063–1068.
33. D.M.Frucht. 2002. IL-23: a cytokine that acts on memory T-cells. Science Signaling. 2002:pe1.
34. I.J.Fuss, C.Becker, Z.Yang, C.Groden, R.L.Hornung, F.Heller, M.F.Neurath, W.Strober, P.J.Mannon. 2006. Both IL‐12p70 and IL‐23 are synthesized during active Crohn's disease and down‐regulated by treatment with anti‐IL‐12 p40 monoclonal antibody. Inflamm Bowel Dis. 12:9–15.
35. M.Gazouli, I.Pachoula, I.Panayotou, G.Mantzaris, G.Chrousos, N.P.Anagnou, Roma-E.Giannikou. 2010. NOD2/CARD15, ATG16L1, and IL23R gene polymorphisms and childhood-onset of Crohn’s disease. World J Gastroenterol. 16:1753.
36. J.Glas, J.Seiderer, M.Wetzke, A.Konrad, H.Torok-P, S.Schmechel, L.Tonenchi, C.Grassl, J.Dambacher, S.Pfennig. 2007. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: Combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One. 2:e819.
37. C.A.Grigoras, P.D.Ziakas, E.Jayamani, E.Mylonakis. 2015. ATG16L1 and IL23R variants and genetic susceptibility to Crohn's Disease: Mode of inheritance based on meta-analysis of genetic association studies. Inflamm Bowel Dis. 21:768–776.
38. Q.Guan, Y.Ma, L.Aboud, C.Weiss, G.Qing, R.Warrington, Z.Peng. 2012. Targeting IL‐23 by employing a p40 peptide‐based vaccine ameliorates murine allergic skin and airway inflammation. Clin Exp Allergy. 42:1397–1405.
39. G.Hamdy, H.Darweesh, E.A.Khattab, S.Fawzy, E.Fawzy, M.Sheta. 2015. Evidence of association of IL-23 receptor gene polymorphisms with Egyptian rheumatoid arthritis patients. Human Immunol. 76:417–420.
40. + effector T-cells develop via a lineage distinct from the T-helper Type 1 and 2 lineages. Nat Immunol. 6:1123–1132.
41. J.Hazlett, L.Stamp, T.Merriman, J.Highton, P.Hessian. 2012. IL-23R rs11209026 poly-morphism modulates IL-17A expression in patients with rheumatoid arthritis. Genes Immun. 13:282–287.
42. P.W.Hellings, A.Kasran, Z.Liu, P.Vandekerckhove, A.Wuyts, L.Overbergh, C.Mathieu, J.L.Ceuppens. 2003. IL-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol. 28:42–50.
43. O.Hradsky, P.Dusatkova, M.Lenicek, et al. 2010. The CTLA4 variants may interact with the IL23R-and NOD2-conferred risk in development of Crohn's disease. BMC Med Genet. 11:91.
44. S.Hue, P.Ahern, S.Buonocore, M.C.Kullberg, D.J.Cua, B.S.McKenzie, F.Powrie, K.J.Maloy. 2006. IL-23 drives innate and T-cell-mediated intestinal inflammation. J Exp Med. 203:2473–2483.
45. H.-R.Kim, H.-S.Kim, M.-K.Park, M.-L.Cho, S.Lee-H, H.-Y.Kim. 2007. The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol. 36:259–264.
46. H17 cells express CD161 and promote intestinal inflammation. J Exp Med. 206:525–534.
47. H17 Cells. Ann Rev Immunol. 27:485–517.
48. H17 cells in human tumor environments. Blood. 114:1141–1149.
49. M.Lacher, S.Schroepf, J.Helmbrecht, D.Von Schweinitz, A.Ballauff, I.Koch, P.Lohse, S.Osterrieder, R.Kappler, S.Koletzko. 2010. Association of the IL‐23 receptor gene variant rs11209026 with Crohn’s disease in German children. Acta Paediatr. 99:727–733.
50. P.L.Lakatos, T.Szamosi, A.Szilvási, E.Molnar, L.Lakatos, A.Kovacs, T.Molnár, I.Altorjay, M.Papp, Z.Tulassay. 2008. ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients. Digest Liver Dis. 40:867–873.
51. E.Lee, W.L.Trepicchio, J.L.Oestreicher, D.Pittman, F.Wang, F.Chamian, M.Dhodapkar, J.G.Krueger. 2004. Increased expression of IL-23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 199:125–130.
52. C.L.Leonardi, A.B.Kimball, K.A.Papp, N.Yeilding, C.Guzzo, Y.Wang, S.Li, L.T.Dooley, K.B.Gordon, P.S.Investigators. 2008. Efficacy and safety of ustekinumab, a human IL-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized double-blind placebo-controlled trial (PHOENIX 1). Lancet. 371:1665–1674.
53. M.Lerch-Bader, C.Lundin, H.Kim, I.Nilsson, G.von Heijne. 2008. Contribution of positively charged flanking residues to the insertion of trans-membrane helices into the endoplasmic reticulum. Proc Natl Acad Sci USA. 105:4127–4132.
54. C.Libioulle, E.Louis, S.Hansoul, C.Sandor, F.Farnir, D.Franchimont, S.Vermeire, O.Dewit, M.De Vos, A.Dixon. 2007. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 3:e58.
55. L.Magyari, G.Melyaregu, B.Melegh. 2008. Susceptibility genetic variants in Hungarian morbus Crohn and ulcerative colitis patients. Orvosi Hetilap. 150:81–88.
56. H17 cells requires TGFβ and induction of the nuclear receptor RORγt. Nat Immunol. 9:641–649.
57. P.J.Mannon, I.J.Fuss, L.Mayer, C.O.Elson, W.J.Sandborn, D.Present, B.Dolin, N.Goodman, C.Groden, R.L.Hornung. 2004. Anti-IL-12 antibody for active Crohn's disease. New Engl J Med. 351:2069–2079.
58. D.McGovern, F.Powrie. 2007. The IL23 axis plays a key role in the pathogenesis of IBD. Gut. 56:1333–1336.
59. A.Mosayebian, R.Meshkat, R.Ghasemi, M.Samadi. 2015. Association between IL-23 receptor R381Q gene polymorphism and asthma. Iran J Allergy Asthma Immunol. (in press).
60. C.A.Murphy, C.L.Langrish, Y.Chen, W.Blumenschein, T.McClanahan, R.A.Kastelein, J.D.Sedgwick, D.J.Cua. 2003. Divergent pro-and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 198:1951–1957.
61. N.Oda, P.B.Canelos, D.M.Essayan, B.A.Plunkett, A.C.Myers, S.-K.Huang. 2005. IL-17F induces pulmonary neutrophilia and amplifies antigen–induced allergic response. Am J Respir Crit Care Med. 171:12–18.
62. J.Oliver, B.Rueda, M.A.Lopez-Nevot, M.Gómez–García, J.Martín. 2007. Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. Clin Gastroenterol Hepatol. 5:977–981.
63. B.Oppmann, R.Lesley, B.Blom, J.C.Timans, Y.Xu, B.Hunte, F.Vega, N.Yu, J.Wang, K.Singh. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13:715–725.
64. H17 cell effector cytokines in inflammation. Immunity. 28:454–467.
65. C.Parham, M.Chirica, J.Timans, E.Vaisberg, M.Travis, J.Cheung, S.Pflanz, R.Zhang, K.P.Singh, F.Vega. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 168:5699–5708.
66. S.Pidasheva, S.Trifari, A.Phillips, J.A.Hackney, Y.Ma, A.Smith, S.J.Sohn, H.Spits, R.D.Little, T.W.Behrens. 2011. Functional studies on the IBD susceptibility gene IL23R implicate reduced receptor function in the protective genetic variant R381Q. PLoS One. 6:e25038.
67. P.Rahman, R.D.Inman, D.D.Gladman, J.P.Reeve, L.Peddle, W.P.Maksymowych. 2008. Association of IL‐23 receptor variants with ankylosing spondylitis. Arthritis Rheum. 58:1020–1025.
68. Y.Y.Raymond, J.Brazaitis, G.Gallagher. 2015. The human IL-23 Receptor rs11209026 A allele promotes the expression of a soluble IL-23R-encoding mRNA apecies. J Immunol. 194:1062–1068.
69. R.L.Roberts, R.B.Gearry, J.E.Hollis Moffatt, A.L.Miller, J.Reid, V.Abkevich, K.M.Timms, A.Gutin, J.S.Lanchbury, T.R.Merriman. 2007. IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. Am J Gastroenterol. 102:2754–2761.
70. B.Rueda, G.Orozco, E.Raya, J.L.Fernandez-Sueiro, J.Mulero, F.J.Blanco, C.Vilches, M.A.González-Gay, J.Martin. 2008. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis. 67:1451–1454.
71. E.Safrany, B.Melegh. 2009. Functional variants of the IL-23 receptor gene in non-gastrointestinal autoimmune diseases. Cur Med Chem. 16:3766–3774.
72. W.J.Sandborn, B.G.Feagan, R.N.Fedorak, E.Scherl, M.R.Fleisher, S.Katz, J.Johanns, M.Blank, P.Rutgeerts, U.GroupUCsDS. 2008. A randomized trial of Ustekinumab, a human IL-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 135:1130–1141.
73. + human T-cell functional responses. Proc Natl Acad Sci USA. 108:9560–9565.
74. C.Schindler, C.Plumlee, editors. 2008. Inteferons open the JAK-STAT pathway. In: Seminars in cell and developmental biology. Amsterdam: Elsevier. p 311–318.
75. C.Schmidt, T.Giese, B.Ludwig, I.Mueller-Molaian, T.Marth, S.Zeuzem, S.C.Meuer, A.Stallmach. 2005. Expression of IL‐12‐related cytokine transcripts in inflammatory bowel disease: elevated IL‐23p19 and IL‐27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis. 11:16–23.
76. H17 cytokine IL‐17F in inflammatory bowel disease (IBD): up-regulated colonic IL‐17F expression in active Crohn's disease and analysis of the IL17F p. His161Arg polymorphism in IBD. Inflamm Bowel Dis. 14:437–445.
77. M.S.Stevic, M.Stefanic, S.Tokic, L.Glavas-Obrovac, S.Mihaljevic, I.Karner. 2014. Pilot study of variants of the IL-23R and STAT3 genes reveals no association with Hashimoto’s thyroiditis in the Croatian population. Endocrine Res. 39:164–167.
78. F.Tavasolian, E.Abdollahi, M.Samadi. 2014. Association of the IL4R single-nucleotide polymorphism I50V with recurrent spontaneous abortion (RSA). J Assisted Repro Genet. 31:851–856.
79. G.Tonel, C.Conrad, U.Laggner, P.Di Meglio, K.Grys, T.K.McClanahan, W.M.Blumenschein, J.-Z.Qin, H.Xin, E.Oldham. 2010. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 185:5688–5691.
80. D.C.Torti, S.R.Feldman. 2007. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 57:1059–1068.
81. M.Tremelling, F.Cummings, S.A.Fisher, J.Mansfield, R.Gwilliam, A.Keniry, E.R.Nimmo, H.Drummond, C.M.Onnie, N.J.Prescott. 2007. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology. 132:1657–1664.
82. G.Trinchieri, S.Pflanz, R.A.Kastelein. 2003. The IL-12 family of heterodimeric cytokines: new players in the regulation of T-cell responses. Immunity. 19:641–644.
83. E.van de Vosse, M.A.Hoeve, T.H.Ottenhoff. 2004. Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis. 4:739–749.
84. M.Venegas, C.J.Beltrán, L.Álvarez, A.Castro, T.Torres, A.D.Leal, F.M.Lahsen, M.A.Hermoso, R.Quera. 2008. IL-23R Arg381Gln polymorphism in Chilean patients with inflammatory bowel disease. Eur Cytokine Netw. 19:190–195.
85. H17 responses. Nat Immunol. 9:650–657.
86. X.Wang, Z.Lin, Q.Wei, Y.Jiang, J.Gu. 2009. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Intl. 29:1343–1347.
87. R.K.Weersma, A.Zhernakova, I.M.Nolte, C.Lefebvre, J.D.Rioux, F.Mulder, D.vanDullemen HM, J.H.Kleibeuker, C.Wijmenga, G.Dijkstra. 2008. ATG16L1 and IL23R are associated with inflammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol. 103:621–627.
88. H17 cells in human disease. Trends Immunol. 32:603–611.
89. N.J.Wilson, K.Boniface, J.R.Chan, B.S.McKenzie, W.M.Blumenschein, J.D.Mattson, B.Basham, K.Smith, T.Chen, F.Morel. 2007. Development, cytokine profile and function of human IL-17-producing helper T-cells. Nat Immunol. 8:950–957.
90. K.Yamazaki, Y.Onouchi, M.Takazoe, M.Kubo, Y.Nakamura, A.Hata. 2007. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13. 1 loci with Crohn’s disease in Japanese patients. J Human Genet. 52:575–583.
91. P.Yu, F.Shen, X.Zhang, R.Cao, X.Zhao, P.Liu, H.Tu, X.Yang, R.Shi, H.Zhang. 2012. Association of single nucleotide polymorphisms of IL23R and IL-17 with ulcerative colitis risk in a Chinese Han population. PLoS One. 7:e44380.